Chronic pain and opioid addiction are deeply intertwined conditions that share overlapping neurobiology. Approximately 21 to 29% of patients prescribed opioids for chronic pain misuse them, and 8 to 12% develop opioid use disorder according to NIDA estimates. The relationship is bidirectional: chronic pain is a major pathway into opioid dependence, and opioid dependence itself worsens pain perception through a phenomenon called opioid-induced hyperalgesia, where the nervous system becomes more sensitive to pain as a result of chronic opioid exposure. Treating one condition without addressing the other leads to poor outcomes for both.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
“The patients who present to Phuket Island Rehab with both chronic pain and opioid dependence face one of the most complex clinical situations in addiction medicine,” says Dr. Ponlawat Pitsuwan. “They are often caught between two fears: the fear of living in unmanaged pain and the fear of continuing a pattern of opioid use that is destroying their lives. Our clinical approach must validate the reality of their pain while providing evidence-based pathways to manage both conditions simultaneously.”
How Chronic Pain Leads to Opioid Dependence
Chronic pain is defined as pain persisting beyond the normal tissue healing period, generally accepted as longer than three months. Unlike acute pain, which serves a protective function, chronic pain involves changes in the central nervous system that maintain pain signalling even after the original injury has resolved. Central sensitisation, a state in which dorsal horn neurons become hyper-excitable, lowers the pain threshold and amplifies pain signals from peripheral nerves. This means the patient genuinely experiences more pain from less stimulus, and this experience is neurologically real, not imagined or exaggerated.
When opioids are prescribed for chronic pain, they initially provide effective relief by binding mu-opioid receptors in the spinal cord and brainstem, inhibiting ascending pain transmission and activating descending pain inhibition pathways. However, with repeated use, the same neuroadaptive processes that drive addiction begin: mu-opioid receptor downregulation, reduced endogenous opioid production, and tolerance. The patient needs higher doses for the same pain relief, and the brain’s reward system begins to associate opioid administration with relief from both physical pain and the emotional distress that accompanies it.
The emotional dimension is critical. Chronic pain activates the same brain regions involved in emotional suffering, particularly the anterior cingulate cortex and the insula. Opioids relieve not only the sensory component of pain but also the affective distress, creating a powerful reinforcement that goes beyond simple analgesia. This dual relief makes opioids psychologically compelling in a way that non-opioid analgesics are not, and it helps explain why patients with chronic pain are more vulnerable to developing opioid use disorder than patients using opioids for acute, time-limited pain.
Opioid-Induced Hyperalgesia: When Opioids Make Pain Worse
Opioid-induced hyperalgesia (OIH) is a paradoxical condition in which chronic opioid use causes the nervous system to become more sensitive to pain rather than less. OIH is distinct from tolerance. Tolerance means the same opioid dose produces less effect; OIH means the patient experiences more pain, including new pain in areas unrelated to the original condition, specifically because of the opioids they are taking.
The mechanisms underlying OIH involve activation of NMDA (N-methyl-D-aspartate) receptors in the spinal cord, upregulation of pronociceptive peptides such as cholecystokinin (CCK) and dynorphin, and neuroinflammatory changes in the central nervous system driven by microglial activation. These changes amplify pain signalling and can persist even after opioid discontinuation, contributing to the difficult clinical picture of withdrawal in patients with co-occurring chronic pain.
Clinically, OIH often presents as a worsening pain picture despite escalating opioid doses, pain that becomes more diffuse and harder to localise, and increased pain sensitivity to stimuli that previously were not painful (allodynia). Recognising OIH is essential because the treatment is the opposite of what the patient’s instinct suggests: rather than increasing the opioid dose, reducing or discontinuing opioids is what ultimately improves the pain. This clinical reality is counterintuitive for patients and requires careful explanation and support.
Clinical insight: At Phuket Island Rehab, patients with chronic pain and opioid dependence frequently report that their pain improves significantly after completing medically supervised opioid tapering. This improvement, which can take several weeks to manifest fully, is consistent with the resolution of opioid-induced hyperalgesia. Many patients are surprised to discover that their baseline pain, while still present, is considerably less severe than what they experienced while on high-dose opioids.
Risk Factors for Developing Addiction During Chronic Pain Treatment
| Risk Factor | Mechanism | Clinical Implication |
|---|---|---|
| Prior substance use history | Pre-sensitised reward circuitry responds more strongly to opioid reinforcement | Careful risk-benefit assessment; consider non-opioid first-line treatment |
| Co-occurring anxiety or depression | Opioids provide relief from emotional distress, creating dual reinforcement | Treat psychiatric conditions concurrently; monitor for emotional rather than physical opioid use |
| Family history of addiction | Genetic predisposition affecting dopamine, opioid receptor, and GABA systems | Enhanced monitoring; shorter prescription durations |
| Higher prescribed opioid dose | Greater receptor occupancy accelerates neuroadaptation and tolerance | Use lowest effective dose; reassess frequently |
| Longer duration of opioid therapy | Extended exposure deepens neuroplastic changes in reward and pain circuits | Set treatment endpoints; avoid indefinite prescriptions without review |
| History of childhood trauma (ACEs) | Altered stress response (HPA axis) increases vulnerability to substance reinforcement | Trauma-informed care approach; address trauma alongside pain management |
The Distinction Between Dependence and Addiction
It is clinically important to distinguish between physical dependence and addiction, though they frequently coexist. Physical dependence is a normal physiological adaptation: anyone who takes opioids daily for several weeks will develop tolerance and experience withdrawal upon cessation. Physical dependence alone does not constitute addiction. A patient taking prescribed methadone for chronic pain who experiences withdrawal if they miss a dose is physically dependent but may not be addicted.
Addiction (opioid use disorder in DSM-5 terminology) involves compulsive use despite harm, loss of control over use, craving, and continued use despite social, occupational, or health consequences. The behaviours that distinguish addiction from simple dependence include taking more than prescribed, using opioids for purposes other than pain (to manage stress, sleep, or emotions), obtaining opioids from multiple sources, continuing use despite recognising that the opioids are causing problems, and being unable to reduce use despite wanting to.
This distinction matters because some patients on long-term opioid therapy are physically dependent but functionally stable and using medications as prescribed. Others have crossed into opioid use disorder and require a different treatment approach. However, physical dependence does create vulnerability: any disruption in opioid supply (a prescription change, a pharmacy issue, a change of physician) can precipitate withdrawal, which in turn drives the kind of drug-seeking behaviour that accelerates the transition to addiction.
Evidence-Based Approaches to Treating Both Conditions
Effective treatment of co-occurring chronic pain and opioid addiction requires an integrated approach that addresses both conditions simultaneously. The major components include medication-assisted treatment for opioid dependence (buprenorphine is particularly valuable here because it provides partial mu-agonist analgesia alongside dependence treatment), multimodal pain management using non-opioid medications (gabapentinoids, duloxetine, low-dose naltrexone, topical agents), physical rehabilitation and exercise therapy, and psychological interventions including cognitive behavioural therapy for pain (CBT-P) and acceptance and commitment therapy (ACT).
Buprenorphine deserves particular attention in this population because it simultaneously treats opioid dependence and provides analgesia. As a partial mu-opioid agonist, buprenorphine activates the receptor sufficiently to prevent withdrawal and provide pain relief while its ceiling effect limits respiratory depression risk. It also has kappa-opioid receptor antagonist properties that may counteract some of the dysphoric components of chronic pain. Clinical evidence supports buprenorphine as effective analgesia for chronic pain conditions including low back pain, osteoarthritis, and neuropathic pain.
When Substance Use Has Become More Than Occasional
If your opioid use for chronic pain has progressed beyond the prescribed regimen, if you find yourself taking higher doses than recommended, using medication earlier than scheduled, requesting early refills, or using opioids to manage emotions rather than specifically for pain, these patterns suggest that dependence has progressed toward opioid use disorder. Similarly, if you have started obtaining opioids from sources other than your prescriber, or if your use continues despite negative consequences for your relationships, work, or health, these are clinical indicators that require professional assessment.
Seeking help for opioid dependence does not mean abandoning pain treatment. Residential treatment programmes like Phuket Island Rehab specialise in the complex clinical work of managing withdrawal while establishing non-opioid pain management strategies, initiating appropriate medication-assisted treatment if indicated, and addressing the psychological dimensions of both chronic pain and substance use through evidence-based therapeutic approaches.
Summary
Chronic pain and opioid addiction share overlapping neurobiology and frequently co-occur. Opioid treatment for chronic pain creates tolerance, physical dependence, and in a significant minority of patients, opioid use disorder. Opioid-induced hyperalgesia can paradoxically worsen the pain that opioids were prescribed to treat. Effective management requires integrated approaches that treat both conditions simultaneously, with buprenorphine playing a particularly valuable dual role. The distinction between physical dependence and addiction matters clinically but should not become a barrier to seeking help when opioid use has exceeded therapeutic boundaries.
“The most important shift we work toward with our chronic pain patients is moving from the question ‘how do I eliminate my pain?’ to ‘how do I live a meaningful life alongside my pain without substances that are making both worse?'” says Dr. Ponlawat Pitsuwan. “When patients discover that their pain actually improves after opioid tapering, that their sleep normalises, that their mood lifts, the relief and surprise are profound. Recovery from opioid dependence is itself one of the most effective pain interventions available.”
Frequently Asked Questions
Does chronic pain cause addiction, or do opioids cause addiction?
Chronic pain itself does not cause addiction, but it creates the circumstances under which opioid addiction develops. The pain drives opioid prescribing, the opioids cause neuroadaptation, and the combination of physical dependence, tolerance escalation, and the emotional relief opioids provide creates vulnerability to addiction. Individual risk factors such as genetics, mental health conditions, trauma history, and social environment determine who progresses from pain-related opioid use to opioid use disorder.
What is opioid-induced hyperalgesia and how do I know if I have it?
Opioid-induced hyperalgesia (OIH) is increased pain sensitivity caused by chronic opioid use. Clinical signs include pain that has become more diffuse or widespread over time, pain in new areas unrelated to your original condition, pain that worsens despite increasing opioid doses, and heightened sensitivity to stimuli that should not be painful (such as light touch or temperature changes). A clinician may suspect OIH if dose escalations consistently fail to improve pain or make it worse. Definitive diagnosis requires a carefully monitored opioid taper to see if pain improves with dose reduction.
Can buprenorphine treat both pain and addiction at the same time?
Yes. Buprenorphine is a partial mu-opioid agonist that provides both dependence management and genuine analgesic efficacy. It prevents withdrawal symptoms and reduces craving through its opioid receptor activity while also providing pain relief through the same mechanism. Its ceiling effect on respiratory depression makes it safer than full agonists. Clinical studies support its use for chronic pain conditions, and it is increasingly recognised as a first-choice treatment for patients with co-occurring chronic pain and opioid use disorder.
Will my pain get worse if I stop taking opioids?
Pain typically increases temporarily during the acute withdrawal period (first 1 to 2 weeks). However, multiple clinical studies show that many patients experience significant improvement in their pain levels after completing opioid tapering, often within 4 to 8 weeks. This improvement is attributed to the resolution of opioid-induced hyperalgesia and the re-establishment of endogenous opioid production. The fear of worsened pain is the most common barrier to opioid reduction, but the evidence suggests that for many chronic pain patients, opioids were actually contributing to their pain problem rather than solving it.
What non-opioid treatments work for chronic pain?
Evidence-based non-opioid approaches include medications (gabapentin or pregabalin for neuropathic pain, duloxetine for both pain and depression, topical NSAIDs or capsaicin, low-dose naltrexone), physical therapies (structured exercise programmes, physiotherapy, aquatic therapy), psychological interventions (cognitive behavioural therapy for pain, acceptance and commitment therapy, mindfulness-based stress reduction), and interventional procedures (nerve blocks, radiofrequency ablation, spinal cord stimulation). Most chronic pain management guidelines now recommend multimodal approaches combining several of these strategies as superior to opioid monotherapy.
Is it safe to stop opioids suddenly if I have been taking them for chronic pain?
No. Abrupt discontinuation of opioids after prolonged use will trigger withdrawal symptoms and may be medically destabilising, particularly if doses were high. All current guidelines recommend gradual tapering under medical supervision, typically reducing the dose by 10 to 25% per week or slower depending on the patient’s response. Too-rapid tapering is associated with inadequately managed withdrawal, which drives patients to seek opioids from other sources or to relapse. A supervised residential setting provides the optimal environment for opioid tapering in patients with significant dependence.
Sources
National Institute on Drug Abuse (NIDA). “Prescription Opioids DrugFacts.” National Institutes of Health. drugabuse.gov
Centers for Disease Control and Prevention. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain.” 2022. cdc.gov
Substance Abuse and Mental Health Services Administration (SAMHSA). “Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders.” Treatment Improvement Protocol (TIP) Series 54. samhsa.gov
Chronic pain · Opioid-induced hyperalgesia · Central sensitisation · Mu-opioid receptor · NMDA receptor · Cholecystokinin · Dynorphin · Microglial activation · Allodynia · Buprenorphine · Gabapentinoids · Duloxetine · Low-dose naltrexone · CBT-P · ACT · Opioid use disorder · DSM-5 · HPA axis · ACEs · Phuket Island Rehab